secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-09-01T12:00:25+00:00
Accession:  0001493152-26-040930
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals reports positive toxicology results for MIRA-55; targets Q1 2027 IND
--------------------------------------------------------------------------------

- 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs completed with positive results.
- Rats identified as more sensitive species; dogs showed greater tolerance; systemic exposure confirmed in both.
- Results inform dose selection for next phase of IND-enabling program; GLP-compliant studies planned.
- Company targets IND submission to FDA for MIRA-55 in Q1 2027, subject to remaining studies.
- MIRA-55 is an oral non-opioid candidate for inflammatory pain; DEA has determined it is not a controlled substance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/0001493152-26-040930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-040930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer